stockportfolio.pro
Stocks / PRME vs TOI
PRME vs TOI
Prime Medicine, Inc. and The Oncology Institute, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Prime Medicine, Inc. (PRME) | The Oncology Institute, Inc. (TOI) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $4.63M | $502.73M |
| Net income (latest FY) | $-201.14M | $-60.61M |
| Revenue growth (5y CAGR) | -2.3% | 21.8% |
| Net margin | -4342.4% | -12.1% |
| Return on equity | -166.4% | 385.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open PRME — free Open TOI — freeFrequently asked questions
Which is bigger, PRME or TOI?
Prime Medicine, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, PRME or TOI?
Over the last five fiscal years, The Oncology Institute, Inc. grew revenue faster — 21.8%/yr versus -2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.